Table 2.
The association between BNP/NT-proBNP levels and prognosis of ICH.
| References | Outcome measure | Follow-up | No. of patients | OR (95% CI) | P -value |
Statistical/ Adjusted factors |
Cutoff value (pg/ml) |
Sensitivity/ Specificity | AUC | BNP/NT-proBNP level# | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I (pg/ml) | II (pg/ml) | ||||||||||
| Mortality | |||||||||||
| Goya et al. (18) | All-cause mortality | 1 month | 271 | 4.7 (1.43–15.63) | 0.011 | MV/1, 2, 3 | BNP: 60.0 |
69/67% | - | 32.4 (17.3–85.0) | 102.5 (48.7–205.0)* |
| Shibazaki et al. (26) | All-cause mortality | In-hospital | 250 | - | - | - | BNP: - | - | - | 67.4 ± 104.1 | 99.9 ± 101.6* |
| Li et al. (19) | All-cause mortality | 6 months | 132 | 1.004 (1.001–1.007) | 0.007 | MV† | NT-proBNP: 999.85 | 93.8/92.0% | 0.958 | 332.88 ± 141.28 | 719.08 ± 178.45* |
| Niu and Teng (28) | All-cause mortality | 6 months | 126 | - | - | - | NT-proBNP:- | - | - | 432.38 ± 183.26 | 1986.48 ± 450.73* |
| Gregorio et al. (20) | All-cause mortality | In-hospital | 201 | 1.650 (1.043–2.612) | 0.032 | MV/1, 2, 3 | NT-proBNP: - | - | - | - | - |
| Functional outcome | |||||||||||
| James et al. (25) | Poor functional outcome: mRS > 2 | Hospital discharge | 28 | 1.023 (1.002–1.044) | 0.04 | UV/NA | BNP: - | - | - | - | - |
| Li et al. (19) | Poor functional outcome: GOS ≤ 3 | Hospital discharge | 132 | 1.004 (1.001–1.006) | 0.008 | MV† | NT-proBNP: 999.85 | 66.1/98.7% | 0.838 | 302.09 ± 81.37 | 595.35 ± 245.29* |
| Yang et al. (29) | Functional outcome: mRS 0–5& | 3 months | 91 | - | - | - | NT-proBNP: - | - | - | 430.47 ± 109.63& | 859.64 ± 128.56&* |
| Gregorio et al. (20) | Poor functional outcome: mRS > 2 | 3 months | 193 | 1.449 (1.106–2.034) | 0.009 | MV/1, 2, 3 | NT-proBNP: - | - | - | - | - |
| Eldawoody et al. (31) | Poor functional outcome: mRS$ | Hospital discharge | 50 | - | 0.4 | MV/NM | NT-proBNP: - | - | - | - | - |
| Adverse cardiac events | |||||||||||
| Park et al. (27) | Adverse cardiac events | In-hospital | 77 | 1.003 (1.001–1.005) | 0.01 | MV† | BNP: 156.6 | 68/66% | 0.749 | 168.5 ± 173.5 | 683.8 ± 1043.8* |
BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; ICH, intracerebral hemorrhage; OR, odds ratio; CI, confidence interval; AUC, area under the curve; MV, multivariate logistic regression; UV, univariate logistic regression; mRS, modified Rankin Scale; GOS, Glasgow Outcome Score; NA, not applicable; NM, not mentioned.
We record “1” for study which adjusted for heart disease including coronary heart disease, congestive heart failure, and atrial fibrillation; “2” adjusted for antiplatelet treatment; “3” adjusted for anticoagulation therapy.
Mortality outcome: event I represented survival and event II represented death; functional outcome: events I and II represented good and poor functional outcome, respectively; adverse cardiac events: events I and II represented absence and presence of cardiac events, respectively.
There was a statistical difference in BNP/NT-proBNP level between event I and event II (P < 0.05).
BNP/NT-proBNP level was presented as mean ± SD or median (interquartile range).
In this study, the mRS was evaluated as a continuous variable (scores of 0–5), and good or poor functional outcome was not defined. Event I represented an mRS score of 2; event II represented an mRS score of 4.
In this study, the mRS was evaluated as a dichotomous variable, but the specific mRS scores for poor functional outcome were not defined.
This study did not include patients with a history of heart disease including congestive heart failure, coronary heart disease and atrial fibrillation.